Title: Health Canada Endorsed Important Safety Information on Rosiglitazone (Avandia, Avandamet and Avandaryl)
|
|
To print: Select File and then Print from your browser's menu Title: Health Canada Endorsed Important Safety Information on Rosiglitazone (Avandia, Avandamet and Avandaryl) |
|
"Health Canada Endorsed Important Safety Information on Rosiglitazone (Avandia, Avandamet and Avandaryl)" Subject: New restrictions on the use of rosiglitazone products due to cardiac safety concerns (Avandia(R), Avandamet(R) and Avandaryl(TM)) ONTARIO, CANADA -- November 6, 2007 -- GlaxoSmithKline Inc., in consultation with Health Canada, has sent out a letter to health care professionals to inform them of important new restrictions on the treatment of type 2 diabetes mellitus with the rosiglitazone-containing products: Avandia(R) (rosiglitazone), Avandamet(R) (rosiglitazone and metformin), and Avandaryl(TM) (rosiglitazone and glimepiride). Further to a Health Canada assessment of adverse event reports, published articles* and other available information on congestive heart failure, myocardial infarction, and related events, the Canadian Product Monographs for rosiglitazone-containing products are being updated and will include the following new usage restrictions: · Rosiglitazone (Avandia®) is no longer approved as monotherapy for type 2 diabetes, except when metformin use is contraindicated or not tolerated. · Rosiglitazone is no longer approved for use in combination with a sulfonylurea, except when metformin is contraindicated or not tolerated. · Treatment with all rosiglitazone products is now contraindicated in patients with any stage of heart failure (i.e., NYHA Class I, II, III or IV). Also, as a reminder: · Rosiglitazone is not indicated for use with insulin. This combination is associated with an increased risk of heart failure. · Rosiglitazone is not indicated for triple therapy (i.e., therapy with rosiglitazone in combination with both metformin and a sulfonylurea). Increases in congestive heart failure and other fluid retention-related events have been reported in patients receiving rosiglitazone as part of triple therapy. Dual therapy When adequate glycemic control is not obtained through diet and exercise plus monotherapy, then rosiglitazone can be used in dual therapy, as follows: · use in combination with metformin; or · when metformin is contraindicated or not tolerated, use in combination with a sulfonylurea. · Rosiglitazone can be added to (not substituted for) the monotherapy agent. Other new information in the Product Monographs will include clinical trial evidence regarding cardiac ischemic events associated with rosiglitazone. Patients are being advised to talk to their doctors about the risks of continuing rosiglitazone therapy if they have underlying heart disease, or are at high risk of heart attack or heart failure (see the Public Communication associated with this Letter). As soon as they are available, the revised Product Monographs for Avandia®, Avandamet(R) and Avandaryl(TM) will replace the versions dated July 2007 (Avandamet(R) and Avandaryl(TM)) and October 2007 (Avandia(R)) that are posted at www.gsk.ca. Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. As always, any serious or unexpected adverse reactions in patients receiving Avandia®, Avandamet® and Avandaryl™ should be reported to GlaxoSmithKline or Health Canada at the following addresses: GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Tel.: 1-800-387-7374 www.gsk.ca Any suspected adverse reaction can also be reported to: Canada Vigilance Program Marketed Health Products Directorate HEALTH CANADA Address Locator: 0701C Ottawa, Ontario, K1A 0K9 Tel: 613-957-0337 or Fax: 613-957-0335 To report an Adverse Reaction, consumers and health professionals may call toll free: Tel: 866-234-2345 Fax: 866-678-6789 CanadaVigilance@hc-sc.gc.ca The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties. For other inquiries related to this communication, please contact Health Canada at: Marketed Health Products Directorate (MHPD) E-mail: MHPD_DPSC@hc-sc.gc.ca Tel: 613-954-6522 Fax: 613-952-7738 REFERENCES: * Recent publications include: 1. Singh, S., Loke, Y.K., & Furberg, C.D., [JAMA (2007) 298:1189 Long-term Risk of Cardiovascular Events with Rosiglitazone: A Meta-analysis. 2. Nissen, S.E. & Wolski, K., NEJM (2007) 356:2457 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |